EGFR and hepatocellular carcinoma: Dasatinib (tyrosine kinase inhibitor) and gefitinib (EGFR inhibitor) showed synergistic effect with irinotecan in HCC models, which implies potential clinical benefit for high-risk patients [35, 36].